| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 133.01 | 4.1% | 47.2% |
| Total Income | 133.01 | 4.1% | 47.2% |
| Expenditure | 130.41 | 1.8% | 26.5% |
| PBT | 2.64 | 148.3% | 119.0% |
| Net Profit | 2.91 | 149.7% | 120.4% |
| OPM | 1.96% | 5.86pp | 15.99pp |
| NPM | 2.18% | 6.77pp | 17.93pp |
| EPS | 0.06 | 150.0% | 120.0% |
Mirum Pharmaceuticals Reports Q3 2025 Results
04 May 2026 · 4 May, 8:09 am
Summary
Mirum Pharmaceuticals, Inc. issued a press release on November 4, 2025, providing a corporate update and announcing its financial results for the quarter ended September 30, 2025. The press release was furnished as an exhibit to a Current Report on Form 8-K.
Informational and educational content only. Not investment advice.